The Latin America, Middle East and Africa Thrombosis And Hemostasis Biomarkers Market would witness market growth of 9.9% CAGR during the forecast period (2023-2030).
A close biochemical relationship between cancer, inflammation, along with the hemostatic system indirectly influences cancer-associated hypercoagulability. Pro-inflammatory cytokines, as well as neutrophil extracellular traps, are used by local and systemic inflammatory processes brought on by cancer to trigger hemostasis. Therefore, cancer patients are characterized by systemic hypercoagulability and hemostatic system dysregulation.
The basic tumor growth, immune evasion, angiogenesis, cancer cell invasion, and the metastatic process are all tumor-promoting pathways that include several hemostatic system components. Therefore, varied levels of systemic hemostatic activation in cancer patients can represent diverse underlying molecular phenotypes of cancer and appear to be associated with cancer aggressiveness. The unfavorable effects of thrombosis in a cancer patient have driven years of large clinical research to adopt the most effective prevention and treatment approaches for venous thromboembolism.
The breast, lung, colon, rectum, and prostate are the five types of cancer that occur most frequently. A third of cancer-related fatalities are attributed to smoking, having a substantial body mass index, drinking, eating few fruits and vegetables, and not exercising enough.
The UAE's healthcare sector has grown to accommodate both the changing requirements of its populace and its aim to become a popular destination for regional medical tourists. The UAE has also committed to healthcare spending in response to the COVID-19 outbreak. Additionally, as one of the wealthiest countries in the region, the need for thrombosis and hemostasis biomarkers would only increase as lifestyle issues proliferated throughout the country. The government has concentrated on building a more robust and sophisticated healthcare infrastructure to meet this need. Therefore, market growth in the region is made possible by increasing public awareness and government assistance.
The Brazil market dominated the LAMEA Thrombosis And Hemostasis Biomarkers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $154.8 million by 2030. The Argentina market is exhibiting a CAGR of 10.5% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 9.6% during (2023 - 2030).
Based on Product, the market is segmented into Reagents & Consumables, and Analyzers. Based on Application, the market is segmented into Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Disseminated Intravascular Coagulation (DIC) & Others. Based on End-use, the market is segmented into Diagnostic Centers, Hospitals & Clinics, and Academic & Research Institutes and Others. Based on Location, the market is segmented into Clinical Laboratory Tests, and Point-of-Care Tests. Based on Type, the market is segmented into Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, D-Dimer, Anti-Thrombin III, Plasminogen & Fibrinogen, Soluble Fibrin, Selectins, Factor VIII, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Thrombosis And Hemostasis Biomarkers Market is Projected to reach USD 7.4 Billion by 2030, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG (Siemens AG), Abbott Laboratories, BioMérieux S.A., Horiba Ltd., QuidelOrtho Corporation, Werfen, S.A., Diazyme Laboratories, Inc. (General Atomics) and BioMedica Diagnostics Inc. (Scotia Investments Family of Companies).
By Product
By Application
By End-Use
By Location
By Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 